SG11202102442WA - Methods and compositions for preventing and treating atherosclerosis and related diseases - Google Patents

Methods and compositions for preventing and treating atherosclerosis and related diseases

Info

Publication number
SG11202102442WA
SG11202102442WA SG11202102442WA SG11202102442WA SG11202102442WA SG 11202102442W A SG11202102442W A SG 11202102442WA SG 11202102442W A SG11202102442W A SG 11202102442WA SG 11202102442W A SG11202102442W A SG 11202102442WA SG 11202102442W A SG11202102442W A SG 11202102442WA
Authority
SG
Singapore
Prior art keywords
compositions
preventing
methods
related diseases
treating atherosclerosis
Prior art date
Application number
SG11202102442WA
Other languages
English (en)
Inventor
Yinghao Zhang
Guirui Yan
Yao Wang
Jingpeng Fu
Original Assignee
Shanghai Clear Fluid Biomedical Science & Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Clear Fluid Biomedical Science & Technology Co Ltd filed Critical Shanghai Clear Fluid Biomedical Science & Technology Co Ltd
Publication of SG11202102442WA publication Critical patent/SG11202102442WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
SG11202102442WA 2018-09-10 2019-09-10 Methods and compositions for preventing and treating atherosclerosis and related diseases SG11202102442WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811052915.1A CN110882378A (zh) 2018-09-10 2018-09-10 一种蛋白在制备预防和治疗动脉粥样硬化及并发症药物的应用
PCT/CN2019/105220 WO2020052570A1 (fr) 2018-09-10 2019-09-10 Méthode et composition destinées à la prévention et au traitement de l'athérosclérose et de maladies associées

Publications (1)

Publication Number Publication Date
SG11202102442WA true SG11202102442WA (en) 2021-04-29

Family

ID=69745256

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102442WA SG11202102442WA (en) 2018-09-10 2019-09-10 Methods and compositions for preventing and treating atherosclerosis and related diseases

Country Status (10)

Country Link
US (1) US20220040257A1 (fr)
EP (1) EP3854804A4 (fr)
KR (1) KR20210075087A (fr)
CN (2) CN110882378A (fr)
AU (1) AU2019339037A1 (fr)
CA (1) CA3112416A1 (fr)
IL (1) IL281394A (fr)
MX (1) MX2021005010A (fr)
SG (1) SG11202102442WA (fr)
WO (1) WO2020052570A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114480382A (zh) * 2020-11-12 2022-05-13 北京大学 用于抑制SURF4基因表达的RNAi试剂和组合物
CN115287276A (zh) * 2022-03-07 2022-11-04 兰州大学 Sem1蛋白、表达sem1蛋白工程化益生菌在制备治疗和/或预防心脏病药物中的应用
WO2024056028A1 (fr) * 2022-09-15 2024-03-21 Shanghai Puyou Biochemical Co., Ltd. Polypeptide analgésique
WO2024188256A1 (fr) * 2023-03-14 2024-09-19 Shanghai Puyou Biochemical Co., Ltd. Utilisation d'un polypeptide pour la prévention ou le traitement de la conjonctivite allergique

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US5781144A (en) * 1996-07-03 1998-07-14 Litton Applied Technology Wide band video signal denoiser and method for denoising
CA2399548A1 (fr) * 2002-08-23 2004-02-23 Andre Tremblay Peptides liberant l'hormone de croissance comme modulateurs negatifs de l'atherosclerose et de l'hypercholesterolemie
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
CN100364563C (zh) * 2004-12-10 2008-01-30 广州中医药大学 抑制丝裂原活化蛋白激酶p38亚族的组合物及其应用
US20090311271A1 (en) * 2008-05-29 2009-12-17 Wyeth Methods and Compositions for Selective Inhibition of Ligand Binding to the Lectin-Like Receptor for Oxidized Low Density Lipoprotein (LOX-1)
CN101654481A (zh) * 2009-07-02 2010-02-24 中国人民解放军第四军医大学 一种抑制动脉粥样硬化的天然抗氧化低密度脂蛋白抗体
CN102863525B (zh) * 2011-07-04 2014-06-04 武汉大学 一种重组人apoE拟肽及制备方法和应用
CN103215292B (zh) * 2012-01-18 2015-10-07 中国科学院生物物理研究所 人Pcid2蛋白的可溶性表达及抗人Pcid2蛋白的单克隆抗体2D7-F11和分泌该抗体的杂交瘤细胞系
CN113150105B (zh) * 2016-07-04 2024-02-20 上海普佑生物医药有限公司 一种新型天然蛋白及其应用
CN110302362B (zh) * 2018-03-20 2024-04-05 上海普佑生物医药有限公司 一种蛋白在制备预防和治疗糖尿病并发症的药物中的应用

Also Published As

Publication number Publication date
CA3112416A1 (fr) 2020-03-19
IL281394A (en) 2021-04-29
MX2021005010A (es) 2022-11-30
CN112839953B (zh) 2024-06-11
JP2022500491A (ja) 2022-01-04
WO2020052570A1 (fr) 2020-03-19
EP3854804A4 (fr) 2022-06-29
EP3854804A1 (fr) 2021-07-28
US20220040257A1 (en) 2022-02-10
CN110882378A (zh) 2020-03-17
KR20210075087A (ko) 2021-06-22
CN112839953A (zh) 2021-05-25
AU2019339037A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
ZA202006627B (en) Methods and compositions for treating cancer
EP4139348A4 (fr) Procédés et compositions pour le traitement d'une inflammation associée à un virus
EP3826666A4 (fr) Compositions et méthodes de traitement de maladies associées à la nrp2
AU2018297285A1 (en) Compositions and methods for treating or preventing endocrine FGF-linked diseases
IL269158A (en) Preparations and methods for the treatment of inflammatory diseases
SG11202102442WA (en) Methods and compositions for preventing and treating atherosclerosis and related diseases
EP3846830A4 (fr) Méthodes et compositions pour le traitement de maladie musculo-squelettiques
IL280413A (en) Bismuth-thiol preparations and wound treatment methods
IL285886A (en) Preparations and methods for the treatment of laminopathy
ZA202100703B (en) Compositions and methods for treating inflammasome related diseases or conditions
EP3609525A4 (fr) Compositions et méthodes pour le traitement ou la prévention de troubles liés à la perméabilité intestinale
IL275767A (en) Compositions and methods for treating metabolic diseases
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
SG11202012435UA (en) Compositions and methods for treating cancer
IL285796A (en) Methods and preparations for the treatment of cancer
IL269743A (en) Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
ZA202205289B (en) Compositions and methods for treating liver disease
EP3768095A4 (fr) Compositions et méthodes pour le traitement des maladies diarrhéiques
EP3781154A4 (fr) Compositions et méthodes pour traiter une lésion rénale
EP3618846A4 (fr) Procédés et compositions pour traiter une maladie hépatique
PL3810128T3 (pl) Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek
EP3672583A4 (fr) Compositions et méthodes pour traiter des maladies neurodégénératives
EP3658118A4 (fr) Méthodes et compositions pour traiter la maladie respiratoire
EP3595640A4 (fr) Compositions et procédés de traitement de la sclérose en plaques
IL282948A (en) Preparations and methods for the treatment of cancer